Barclays lowered the firm’s price target on Guardant Health (GH) to $55 from $60 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health: Poised for Growth with Innovative Precision Oncology Solutions
- Guardant Health initiated with an Outperform at Mizuho
- Guardant Health’s Strategic Growth: Shield’s Coverage Expansion and Revenue Potential
- Guardant Health’s Shield blood test covered by VA Care Beneficiaries
- Strategic Milestone Boosts Guardant Health’s Growth Potential with ADLT Status Approval